Lobe Sciences Stock Price, News & Analysis

Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company developing therapeutics for rare and underserved diseases, has engaged ArcStone Securities and Investments Corp. for capital markets advisory services. The partnership aims to enhance Lobe's market visibility and institutional investor engagement across North American markets.

Under the agreement, ArcStone will provide comprehensive advisory services including capital markets planning and strategic positioning. The collaboration is effective immediately, with ArcStone's expertise expected to support Lobe's development programs and strengthen its presence in both Canadian and U.S. financial markets.

Lobe Sciences Ltd. (OTCQB:LOBEF), a biopharmaceutical company, has announced a debt settlement through a share issuance. The company has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for previous legal services by issuing 546,206 common shares at a deemed price of CAD$0.02123 per share.

The shares were issued on May 13, 2025, and are subject to regulatory hold periods under Canadian securities laws.

Lobe Sciences (OTCQB:LOBEF) has announced the validation of its European Unitary Patent EP4117446 across 17 EU member states for its DHA-based composition targeting Sickle Cell Disease (SCD).

The patent specifically covers Altemia®, a physician-supervised medical food formula designed to address long-chain fatty acid deficiencies in SCD patients. The formulation combines DHA and natural emulsifiers to improve bioavailability and restore red blood cell membrane integrity.

This validation represents a significant expansion of Lobe's intellectual property protection in key European markets, strengthening the company's position for broader commercialization of Altemia®.

Lobe Sciences (LOBEF) has spun out its Conjugated Psilocin™ compound to newly created Cynaptec Pharmaceuticals, securing a $6M investment with an option for additional $20M for Phase 3 trials. Cynaptec will advance the development of this novel psilocin analog, designed to treat chronic cluster headaches without hallucinations. Lobe retains 64% ownership in Cynaptec post-investment. The compound targets an orphan disease affecting 60,000+ US patients with no FDA-approved treatments. Additionally, Lobe is launching Altemia® Medical Food for Sickle Cell Disease, which affects 100,000 people in the US and 10M worldwide, particularly impacting African American children.

Lobe Sciences Ltd. (OTCQB:LOBEF) has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025. Yao brings over 25 years of leadership experience in corporate finance and biotech, having held executive positions at Mountain Valley MD, Scotiabank, and Morgan Stanley. As a co-founder of SelecIn Biomedical Inc., he has experience in developing small molecule therapies and securing early-stage funding. The appointment represents a strategic transition from part-time to full-time financial leadership, aimed at strengthening the company's regulatory compliance, capital markets readiness, and operational expansion. Yao holds an MBA from McGill University, a BS in Biology from Nankai University, and professional designations as FCMA and CGMA.

Lobe Sciences (LOBEF) has announced a significant private placement through its newly created subsidiary Cynaptec Pharmaceuticals. The deal includes an initial US$6 million investment and an additional US$20 million option, potentially totaling US$26 million.

Cynaptec will own and develop the company's Conjugated Psilocin™ technology, receiving worldwide patents and related IP from Lobe Sciences in exchange for 6,399,900 shares of Common Stock. The initial placement involves issuing 3,600,000 Series A-1 Preferred Stock shares at US$1.66 per share.

The funding will support preclinical research, Phase 1, and Phase 2a clinical studies, with the optional US$20 million designated for Phase 3 clinical trials in chronic cluster headache treatment. Post-investment, Lobe Sciences retains 64% ownership of Cynaptec, which could decrease to 32% if the investor fully exercises their option within 120 days following completion of specific clinical milestones.

Lobe Sciences (LOBEF) has provided a comprehensive corporate update detailing several key transactions and operational developments. The company issued multiple convertible notes throughout 2024, including C$678,450 in March, C$1,462,716 in May, and US$250,000 in December, all bearing 10% annual interest.

The company settled various debts through share issuances, including 16.4M shares to Clearway Global, 10.8M shares to former directors and officers, and implemented a director compensation agreement involving 7M shares per director. Additionally, 3.5M restricted share units were issued to a subsidiary officer.

On the operational front, Lobe Sciences highlighted progress with Conjugated Psilocin™, securing two US patents and filing international applications. The company published Phase 1 clinical trial results and received pre-IND feedback from the FDA, marking significant steps toward human clinical trials.

Lobe Sciences and its subsidiary Alera Pharma have received a second patent allowance for Conjugated Psilocin™ from the U.S. Patent Office. The patent covers compositions comprising psilocin mucate salt or conjugate and their production methods. Conjugated Psilocin™ is a stable, highly bioavailable analogue of psilocin, the active metabolite of psilocybin, with potential applications in treating neurological disorders, particularly chronic cluster headache. The intellectual property rights will be assigned to Alera Pharma, which is currently pursuing fundraising activities for drug development.

Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), a biopharmaceutical company, has announced the appointment of Enclave Capital and Peak Asset Management to initiate fundraising for the development of their patented pharmaceutical candidate, Conjugated Psilocin™. This move follows the company's recent establishment of Alera Pharma, Inc. as an operating entity for drug development.

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences, emphasized the significance of this appointment in advancing their development plans, particularly in light of the recently issued new chemical entity patent for Conjugated Psilocin™. The company aims to progress this drug candidate through the US FDA NDA development process efficiently, focusing on treating diseases with significant unmet medical needs.